Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the EMBRAVE3 trial design to be a...
December 08, 2025 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically...
December 04, 2025 16:10 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming...
April 08, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight

New York, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight The treatment...
January 09, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Latest Published 4 Rare Neurological Disorders Market Reports by DelveInsight: Amyotrophic Lateral Sclerosis, Developmental and Epileptic Encephalopathies, Primary Ciliary Dyskinesia, and Chronic Inflammatory Demyelinating Polyneuropathy

New York, USA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Latest Published 4 Rare Neurological Disorders Market Reports by DelveInsight: Amyotrophic Lateral Sclerosis, Developmental and Epileptic...
October 11, 2022 11:15 ET | Source: Ambit Inc.

Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting

CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit's data-driven methodology for...